NCT00144768View on ClinicalTrials.gov

A Study Investigating the Relationship Between the Development of Laronidase Antibody and Urinary GAG (Glycosaminoglycan) Levels in Aldurazyme® Treated Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

July 31, 2004

Primary Completion Date

May 31, 2007

Study Completion Date

May 31, 2007

Conditions
Mucopolysaccharidosis IHurler's SyndromeHurler-Scheie SyndromeScheie's Syndrome
Interventions
DRUG

laronidase

dose of 0.58mg/kg body weight IV every week

Trial Locations (3)

53226

Children's Hospital of Wisconsin, Milwaukee

90027

Childrens Hospital Los Angeles, Los Angles

06106

Connecticut Children's Medical Center, Hartford

All Listed Sponsors
collaborator

BioMarin/Genzyme LLC

INDUSTRY

lead

Genzyme, a Sanofi Company

INDUSTRY

NCT00144768 - A Study Investigating the Relationship Between the Development of Laronidase Antibody and Urinary GAG (Glycosaminoglycan) Levels in Aldurazyme® Treated Patients | Biotech Hunter | Biotech Hunter